Search clinical trials for: Sitagliptin

Total 818 results

Merck Sharp & Dohme LLC

Completed

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Renal Insufficiency | Hemodialysis
Seoul National University Bundang Hospital

Completed

Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination (COSMETIC)

Diabetes

Korea, Republic of
Samuel Lunenfeld Research Institute, Mount Sinai...
Merck Sharp & Dohme LLC

Completed

Beta-Cell Function and Sitagliptin Trial (BEST) (BEST)

Type 2 Diabetes Mellitus

Canada
AstraZeneca

Completed

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Type 2 Diabetes Mellitus

United States
University of Pennsylvania

Recruiting

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

Heart Failure | Type2 Diabetes | Genetics Disease

United States
University Health Network, Toronto
Novo Nordisk A/S

Enrolling by invitation

Semaglutide vs Sitagliptin

Diabetes Mellitus | NAFLD | NASH - Nonalcoholic Steatohepatitis | Liver Transplant; Complications

Canada
Li Bo

Completed

Effect of Sitagliptin on Progression of Coronary Intermediate Lesion

Type 2 Diabetes Mellitus | Atherosclerosis

China
GlaxoSmithKline

Completed

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

Diabetes Mellitus, Type 2

United States
University of Alabama at Birmingham

Terminated

Changes in Bone Turnover With Increased Incretin Hormone Exposure (DRTC)

Type 2 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

Type 2 Diabetes Mellitus (T2DM)
Merck Sharp & Dohme LLC

Completed

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Type 2 Diabetes
University Medical Centre Ljubljana

Completed

Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome

PCOS
Takeda

Terminated

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Glycemic Control

United States, Bulgaria, Malaysia, Korea, Republic of, Australia, Czech Republic, Hungary, Thailand, Italy, Slovakia, Croatia
Merck Sharp & Dohme LLC

Completed

MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)

Type 2 Diabetes Mellitus
University Hospital, Gentofte, Copenhagen
Merck Sharp & Dohme LLC

Completed

Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes

Type 2 Diabetes

Denmark
Instituto Nacional de Ciencias Medicas y Nutricion...
Merck Sharp & Dohme LLC

Completed

Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism

Reactive Hypoglycemia

Mexico
Boehringer Ingelheim

Completed

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Healthy

Germany
Icahn School of Medicine at Mount Sinai
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Withdrawn

Mechanisms Underlying Predictors of Success From Obesity Surgery

Obesity

United States
Cadila Pharnmaceuticals
New Millennium Indian Technology Leadership Initiative (NMITLI) program of...

Completed

Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus

Uncontrolled Type 2 Diabetes Mellitus

India
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)

Type 2 Diabetes Mellitus
Michael A. Nauck

Completed

Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D

Type 2 Diabetes

Germany
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

Diabetes Mellitus, Type 2
Takeda

Completed

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Mexico
Forest Laboratories
Phenomix

Terminated

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone (REDWOOD403)

Diabetes Mellitus, Type 2

United States
Boehringer Ingelheim

Completed

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2

Belgium, Canada, France, India, Italy, Korea, Republic of, Malaysia, Netherlands, Spain
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers

Hypertension | Diabetes

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Diabetes Mellitus, Type 2

Bangladesh, Belgium, Canada, China, Germany, Guatemala, Hong Kong, India, Lebanon, Mexico, Peru, Philippines, Spain, Taiwan
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Boehringer Ingelheim

Completed

Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components

Healthy

Germany
Shahid Beheshti University of Medical Sciences
Isfahan University of Medical Sciences

Completed

Iranian Intensive Care Unit (ICU) Glutamine Study

Trauma Patients in ICU

Iran, Islamic Republic of
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

Obesity

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes

Type 2 Diabetes

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Healthy

United States
University of Southern California

Completed

Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity (SAVORO)

Inflammation | Atherosclerosis

United States
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

Type 2 Diabetes Mellitus
University of British Columbia
Merck Sharp & Dohme LLC

Terminated

Effect of Sitagliptin on Graft Function Following Islet Transplantation

Islet Transplantation

Canada
Medical College of Wisconsin
Merck Sharp & Dohme LLC

Completed

Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

Diabetes | Atherosclerosis

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers

Healthy
Novartis Pharmaceuticals

Completed

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Korea, Republic of, Latvia, Peru, Lithuania, Israel, Norway, Finland, Argentina, Austria, Belgium, Germany, Greece, Guatemala, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, Venezuela
Eli Lilly and Company

Completed

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

Singapore
GlaxoSmithKline

Completed

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes (SGA112534)

Diabetes Mellitus, Type 2

Germany, United States, France, United Kingdom
GlaxoSmithKline

Completed

A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.

Diabetes Mellitus, Type 2

United States, Germany, Peru, Israel, Taiwan, Australia, Russian Federation, United Kingdom, Korea, Republic of, Spain, Brazil, Colombia, India, Philippines, South Africa
India Diabetes Research Foundation & Dr. A. Ramachandran...

Withdrawn

Sitagliptin in Prevention of Type 2 Diabetes Mellitus (SITAGLIPTIN)

Type 2 Diabetes

India
Merck Sharp & Dohme LLC

Completed

A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

Type 2 Diabetes Mellitus
Niigata Medical Center
Nagaoka Red Cross Hospital

Unknown

Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

Japan
Ono Pharmaceutical Co. Ltd

Completed

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Type 2 Diabetes Mellitus

3

Subscribe